

Status: Currently Official on 17-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-93466BCB-628C-4731-997C-39F174FDCA2D\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M33785\\_02\\_01](https://doi.org/10.31003/USPNF_M33785_02_01)  
DOI Ref: 1dl6j

© 2025 USPC  
Do not distribute

# Fluoxetine Oral Solution

## DEFINITION

Fluoxetine Oral Solution contains an amount of Fluoxetine Hydrochloride equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of fluoxetine (C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>NO). It may contain one or more preservatives.

## IDENTIFICATION

Change to read:

- A. [▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197S](#)▲ (CN 1-MAY-2020)

**Sample solution:** Transfer a volume of Oral Solution, equivalent to 20 mg of fluoxetine, to a separatory funnel. Add 5.0 mL of water and 0.5 mL of 1 N sodium hydroxide, extract with 5 mL of chloroform, and discard the aqueous layer. Evaporate the remaining layer to dryness, and dissolve the residue in 0.4 mL of chloroform.

**Acceptance criteria:** Meets the requirements

## ASSAY

### PROCEDURE

**Buffer:** Triethylamine and water (1:98), adjusted with phosphoric acid to a pH of 6.0

**Mobile phase:** Acetonitrile and Buffer (50:50)

**Standard solution:** 45 µg/mL of [USP Fluoxetine Hydrochloride RS](#) in Mobile phase

**Sample solution:** Nominally 40 µg/mL of fluoxetine from Oral Solution in Mobile phase

### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 215 nm

**Column:** 4.6-mm × 25-cm; packing L10

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

### System suitability

**Sample:** Standard solution

### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

### Analysis

**Samples:** Standard solution and Sample solution

Calculate the percentage of the labeled amount of fluoxetine (C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>NO) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response from the Sample solution

$r_S$  = peak response from the Standard solution

$C_S$  = concentration of [USP Fluoxetine Hydrochloride RS](#) in the Standard solution (µg/mL)

$C_U$  = nominal concentration of fluoxetine in the Sample solution (µg/mL)

$M_{r1}$  = molecular weight of fluoxetine, 309.33

$M_{r2}$  = molecular weight of fluoxetine hydrochloride, 345.79

**Acceptance criteria:** 90.0%–110.0%

## PERFORMANCE TESTS

- [DELIVERABLE VOLUME \(698\)](#)

For multiple-unit containers

**Acceptance criteria:** Meets the requirements

- **UNIFORMITY OF DOSAGE UNITS (905).**

**For single-unit containers**

**Acceptance criteria:** Meets the requirements

## IMPURITIES

### • ORGANIC IMPURITIES

**Solution A:** 4.3 g/L of sodium 1-octanesulfonate and 13.8 g/L of monobasic sodium phosphate in water adjusted with phosphoric acid to a pH of 3.0

**Solution B:** Methanol, acetonitrile, and *Solution A* (26:21:53)

**Solution C:** Methanol, acetonitrile, and *Solution A* (22:35:43)

**Mobile phase:** See [Table 1](#).

**Table 1**

Time (min)	Solution B (%)	Solution C (%)
0	100	0
13	100	0
15	0	100
29	0	100
30	100	0
End	100	0

**Diluent:** Methanol, acetonitrile, and *Solution A* (30:10:60)

**Impurity identification solution:** Nominally 2.0 mg/mL of [USP Fluoxetine Hydrochloride RS](#) prepared as follows. Transfer a suitable quantity of [USP Fluoxetine Hydrochloride RS](#) to a container, dissolve in 1 N sulfuric acid, and heat at 85° for 1 h.

**System suitability solution:** 0.1 mg/mL of [USP Fluoxetine Hydrochloride RS](#) prepared as follows. Transfer 10 mg of [USP Fluoxetine Hydrochloride RS](#) to a 100-mL volumetric flask. Add 1.0 mL of *Impurity identification solution*. Dissolve in and dilute with *Diluent* to volume.

**Sample solution:** Nominally 1.9 mg/mL of fluoxetine from Oral Solution in *Diluent*

**Dilute sample solution:** Nominally 76 µg/mL of fluoxetine from *Sample solution* in *Diluent*

### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 215 nm

**Column:** 4.6-mm × 25-cm; packing L1

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

### System suitability

**Sample:** *System suitability solution*

**Suitability requirements:** The retention time of any peak, except the fluoxetine peak, is less than 13 min.

### Analysis

**Samples:** *Sample solution* and *Dilute sample solution*

Calculate the percentage of each impurity in the portion of Oral Solution taken:

$$\text{Result} = \{r_i/[r_T + (D \times r_{UD})]\} \times 100$$

$r_i$  = peak response of each impurity from the *Sample solution*

$r_T$  = sum of all the peak responses excluding fluoxetine from the *Sample solution*

$D$  = dilution factor between the *Sample solution* and the *Dilute sample solution*, 25

$r_{UD}$  = peak response of fluoxetine from the *Dilute sample solution*

### Acceptance criteria

**Any individual impurity:** NMT 0.4%

**Total impurities:** NMT 0.8%

SPECIFIC TESTS

- [pH\(791\)](#): 2.5–4.5

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.
- **USP REFERENCE STANDARDS (11).**  
[USP Fluoxetine Hydrochloride RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FLUOXETINE ORAL SOLUTION	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 51(1)

Current DocID: GUID-93466BCB-628C-4731-997C-39F174FDCA2D\_2\_en-US

DOI: [https://doi.org/10.31003/USPNE\\_M33785\\_02\\_01](https://doi.org/10.31003/USPNE_M33785_02_01)

DOI ref: [1dl6j](#)